RxSight stock reports Q2 revenue as analysts set a Reduce consensus

Published on 10/07/2026 at 03:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RxSight stock posted USD 33.74 million in Q2 revenue on August 5, 2026. Twelve firms assign a Reduce consensus and USD 8.17 average target.

RXST, US78349D1072, Illustration mit AI erstellt.

RxSight (ISIN US78349D1072) generated USD 33.74 million in second-quarter 2026 revenue, versus USD 32.55 million expected, according to MarketBeat on October 3, 2026. The result gives RxSight stock a clear operating checkpoint while the share price remains close to its yearly low.

Revenue beats the quarterly estimate

RxSight's Q2 revenue exceeded consensus by USD 1.19 million, while adjusted earnings per share came in at a loss of USD 0.29 against a consensus loss of USD 0.33, MarketBeat reported. The revenue beat was positive, but the quarterly loss keeps profitability as the central financial issue for the medical technology company.

The company develops the Light Adjustable Lens system and Light Delivery Device for cataract surgery. RxSight describes the system as enabling doctors to customize vision after implantation through post-operative light treatments, according to its investor-relations page.

Alcon deal adds strategic support

At the Wells Fargo Healthcare Conference on September 9, 2026, management highlighted the July Alcon collaboration, which provides USD 200 million in upfront payments and a 30 percent royalty on future sales, according to Investing.com. The same account said RxSight had USD 210 million in cash at quarter-end, while commercialization planning remained in the proof-of-concept phase.

That structure changes the financial backdrop, but it does not remove execution risk. RxSight must convert its installed surgeon base and the Alcon relationship into higher lens utilization before the partnership can materially alter the revenue trend.

Consensus target exceeds the share price

MarketBeat reported on October 3, 2026, that twelve firms rated the stock Reduce on average, with three sells, seven holds and two buys. The average target of USD 8.17 stands 71.6 percent above the USD 4.76 share price, while the published target range runs from USD 5.50 to USD 11.00.

For investors, the contrast is sharp: the latest quarter beat revenue and adjusted EPS expectations, yet the consensus still reflects caution about the path to sustained growth and profitability.

RxSight stock stays below its yearly midpoint

RxSight stock closed at USD 4.76 on Nasdaq on October 5, 2026. The 52-week range of USD 4.48 to USD 13.22 places the stock 64.0 percent below its yearly high, while market capitalization stood at USD 198.0 million on the same date.